Home' Australian Pharmacist : Australian Pharmacist March 2013 Contents Australian Pharmacist March 2013 I © Pharmaceutical Society of Australia Ltd.
Juvenile arthritis increasing
Hospitalisation rates for juvenile arthritis
are increasing, according to the Australian
Institute of Health and Welfare (AIHW).
The AIHW report, A snapshot of juvenile
arthritis,examines the prevalence,
treatment and experience of arthritis in
children aged 0–15 years old.
AIHW spokesperson Nigel Harding said:
‘Juvenile arthritis is estimated to affect
about 0.3% of Australian children. The
evidence is limited, but suggests that
more girls suffer from juvenile arthritis
The report shows that in the 10 years from
2000–01 to 2009–10, hospitalisations for
children with juvenile arthritis tripled.
The rate rose from 8.8 per 100,000 people
in 2000–01 to 28.9 per 100,000 people
in 2009–10. Girls accounted for most of
In the past decade biologic
disease-modifying anti-rheumatic drugs
(bDMARDs) have become available for
treating juvenile arthritis in Australia,
broadening the treatment options. While
the total expenditure on medicines used
to manage juvenile arthritis is not known,
the Australian Government subsidies paid
for bDMARDs have increased each year
since their introduction, to $4.7 million
‘ There are a few possible explanations for
the increase in the hospitalisation rate,’ Mr
‘ These include an increase in the number
of children with the condition, changes
in hospital admission practices for this
condition, changes in the procedures
available to treat the condition in
hospital, and broader changes in the way
this condition is managed in the health
It is not yet known which of these factors
are contributing to the increasing
hospitalisation rate for juvenile arthritis
Unstick bacterial conjunctivitis with
the proven efficacy of Chlorsig.
PBS Information: This product is listed on the PBS
as an anti-infective for ophthalmological use.
Please Review Product Information before prescribing.
Full Product Information is available
from Aspen Pharmacare upon request.
Abridged Product Information: Chlorsig® (chloramphenicol). Indications: For the treatment of bacterial conjunctivitis.
Contraindications: Hypersensitivity and/or toxic reaction to the drug. Precautions: Bone marrow hypoplasia, including
aplastic anaemia and death, has been rarely reported following local application of chloramphenicol. Chloramphenicol should
not be used when less potentially dangerous agents would be expected to provide effective treatment. Ophthalmic agents
may retard corneal wound healing. Eye pain/injury, severe ocular infections, contact lenses, dry eye syndrome, glaucoma,
concomitant use of other ocular medications, surger y or laser within the last 6 months. See full PI. Adverse Effects: Local
irritation (itching/burning), angioneurotic oedema; anaphylaxis, urticaria, fever, vesicular and maculopapular dermatitis, blood
dyscrasias. Pregnancy Category: A. Dosage and administration: Eye Drops. Adults and children (2 years and over):
Instil 1 or 2 drops in the affected eye( s) ever y two to six hours for up to 5 days. Eye Ointment. Adults and children (2 years and
over): Apply 1.5 cm into lower eye lid of the affected eye every three hours for up to 5 days. Chlorsig is not recommended for
children under 2 years except on medical advice. Presentation : Eye Drops. Store between 2-8°C until opened. Refrigerate.
Do not freeze. On opening, the drops may be stored at room temperature (below 25°C). Eye Ointment. Store below 25°C.
PBS Dispensed Price: Eye Drops $11.10, Eye Ointment $ 9.86 . Schedule: S3. ® Chlorsig is a registered trademark of
Aspen Pharma Pty Ltd. Aspen Australia is a group of companies including Aspen Pharma Pty Ltd (ABN 88 004 118 594).
References: 1. Chlorsig Product Information (Oct, 2010). 2. Rose PW et al. Lancet 2005; 366:37-43. 3.
Miller IM et al. Eye (Lond). 1992; 6 (Pt 1):111-4. All sales and marketing
requests to: Aspen Pharma Pty Ltd, 34-36 Chandos Street, St Leonards
NSW 2065 | Tel +61 2 8436 8300. firstname.lastname@example.org |
13/09/12 5:37 PM
Links Archive February 2013 Australian Pharmacist April 2013 Navigation Previous Page Next Page